FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1845099892> ?p ?o ?g. }

• W1845099892 endingPage "2593" @default.
• W1845099892 startingPage "2586" @default.
• W1845099892 abstract "BACKGROUND Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in this setting. METHODS Data were collected using an electronic data‐capture platform from 28 international centers. Eligible patients had clinical T‐classification 2 (cT2) through cT4aN0M0 urothelial cancer of the bladder and received neoadjuvant GC or methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) before undergoing cystectomy. Logistic regression was used to compute propensity scores as the predicted probabilities of patients being assigned to MVAC versus GC given their baseline characteristics. These propensity scores were then included in a new logistic regression model to estimate an adjusted odds ratio comparing the odds of attaining a pathologic complete response (pCR) between patients who received MVAC and those who received GC. RESULTS In total, 212 patients (146 patients in the GC cohort and 66 patients in the MVAC cohort) met criteria for inclusion in the analysis. The majority of patients in the MVAC cohort (77%) received dose‐dense MVAC. The median age of patients was 63 years, they were predominantly men (74%), and they received a median of 3 cycles of neoadjuvant chemotherapy. The pCR rate was 29% in the MVAC cohort and 31% in the GC cohort. There was no significant difference in the pCR rate when adjusted for propensity scores between the 2 regimens (odds ratio, 0.91; 95% confidence interval, 0.48‐1.72; P = .77). In an exploratory analysis evaluating survival, the hazard ratio comparing hazard rates for MVAC versus GC adjusted for propensity scores was not statistically significant (hazard ratio, 0.78; 95% confidence interval, 0.40‐1.54; P = .48). CONCLUSIONS Patients who received neoadjuvant GC and MVAC achieved comparable pCR rates in the current analysis, providing evidence to support what has become routine practice. Cancer 2015;121:2586–2593 . © 2015 American Cancer Society ." @default.
• W1845099892 created "2016-06-24" @default.
• W1845099892 creator A5012800133 @default.
• W1845099892 creator A5016057883 @default.
• W1845099892 creator A5018275141 @default.
• W1845099892 creator A5031306593 @default.
• W1845099892 creator A5041033274 @default.
• W1845099892 creator A5043164534 @default.
• W1845099892 creator A5043616693 @default.
• W1845099892 creator A5046542135 @default.
• W1845099892 creator A5050435057 @default.
• W1845099892 creator A5055738663 @default.
• W1845099892 creator A5059810021 @default.
• W1845099892 creator A5073593424 @default.
• W1845099892 creator A5074756323 @default.
• W1845099892 creator A5078099654 @default.
• W1845099892 creator A5080507578 @default.
• W1845099892 creator A5081519723 @default.
• W1845099892 creator A5083331837 @default.
• W1845099892 creator A5083920381 @default.
• W1845099892 creator A5084909001 @default.
• W1845099892 creator A5088951258 @default.
• W1845099892 date "2015-04-14" @default.
• W1845099892 modified "2023-10-11" @default.
• W1845099892 title "Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer" @default.
• W1845099892 cites W1538189929 @default.
• W1845099892 cites W1554784429 @default.
• W1845099892 cites W1975918912 @default.
• W1845099892 cites W1981535076 @default.
• W1845099892 cites W1986710101 @default.
• W1845099892 cites W2026826756 @default.
• W1845099892 cites W2034679752 @default.
• W1845099892 cites W2036193982 @default.
• W1845099892 cites W2037929227 @default.
• W1845099892 cites W2053879494 @default.
• W1845099892 cites W2073175347 @default.
• W1845099892 cites W2073804272 @default.
• W1845099892 cites W2083801158 @default.
• W1845099892 cites W2101562875 @default.
• W1845099892 cites W2103257412 @default.
• W1845099892 cites W2103561213 @default.
• W1845099892 cites W2106787323 @default.
• W1845099892 cites W2122063636 @default.
• W1845099892 cites W2128042367 @default.
• W1845099892 cites W2135640630 @default.
• W1845099892 cites W2135821800 @default.
• W1845099892 cites W2150291618 @default.
• W1845099892 cites W2157244703 @default.
• W1845099892 cites W2159433570 @default.
• W1845099892 cites W2160107406 @default.
• W1845099892 cites W2160379180 @default.
• W1845099892 cites W2160658069 @default.
• W1845099892 cites W2164791945 @default.
• W1845099892 cites W2204969230 @default.
• W1845099892 cites W3122948292 @default.
• W1845099892 doi "https://doi.org/10.1002/cncr.29387" @default.
• W1845099892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25872978" @default.
• W1845099892 hasPublicationYear "2015" @default.
• W1845099892 type Work @default.
• W1845099892 sameAs 1845099892 @default.
• W1845099892 citedByCount "148" @default.
• W1845099892 countsByYear W18450998922015 @default.
• W1845099892 countsByYear W18450998922016 @default.
• W1845099892 countsByYear W18450998922017 @default.
• W1845099892 countsByYear W18450998922018 @default.
• W1845099892 countsByYear W18450998922019 @default.
• W1845099892 countsByYear W18450998922020 @default.
• W1845099892 countsByYear W18450998922021 @default.
• W1845099892 countsByYear W18450998922022 @default.
• W1845099892 countsByYear W18450998922023 @default.
• W1845099892 crossrefType "journal-article" @default.
• W1845099892 hasAuthorship W1845099892A5012800133 @default.
• W1845099892 hasAuthorship W1845099892A5016057883 @default.
• W1845099892 hasAuthorship W1845099892A5018275141 @default.
• W1845099892 hasAuthorship W1845099892A5031306593 @default.
• W1845099892 hasAuthorship W1845099892A5041033274 @default.
• W1845099892 hasAuthorship W1845099892A5043164534 @default.
• W1845099892 hasAuthorship W1845099892A5043616693 @default.
• W1845099892 hasAuthorship W1845099892A5046542135 @default.
• W1845099892 hasAuthorship W1845099892A5050435057 @default.
• W1845099892 hasAuthorship W1845099892A5055738663 @default.
• W1845099892 hasAuthorship W1845099892A5059810021 @default.
• W1845099892 hasAuthorship W1845099892A5073593424 @default.
• W1845099892 hasAuthorship W1845099892A5074756323 @default.
• W1845099892 hasAuthorship W1845099892A5078099654 @default.
• W1845099892 hasAuthorship W1845099892A5080507578 @default.
• W1845099892 hasAuthorship W1845099892A5081519723 @default.
• W1845099892 hasAuthorship W1845099892A5083331837 @default.
• W1845099892 hasAuthorship W1845099892A5083920381 @default.
• W1845099892 hasAuthorship W1845099892A5084909001 @default.
• W1845099892 hasAuthorship W1845099892A5088951258 @default.
• W1845099892 hasBestOaLocation W18450998921 @default.
• W1845099892 hasConcept C121608353 @default.
• W1845099892 hasConcept C126322002 @default.
• W1845099892 hasConcept C126894567 @default.
• W1845099892 hasConcept C143998085 @default.
• W1845099892 hasConcept C156957248 @default.
• W1845099892 hasConcept C207103383 @default.

• next